(Q32019452)

5 July 2017

title

Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast (English)

1 reference

5 July 2017

Simons FE

1

1 reference

5 July 2017

Johnston L

series ordinal

2

1 reference

5 July 2017

Gu X

series ordinal

3

1 reference

5 July 2017

Simons KJ

series ordinal

4

1 reference

5 July 2017

publication date

1 January 2001

1 reference

Annals of Allergy, Asthma & Immunology

5 July 2017

published in

1 reference

5 July 2017

volume

86

1 reference

5 July 2017

issue

1

1 reference

5 July 2017

page(s)

44-50

1 reference

Patterns of inflammatory responses following rechallenge of skin late-phase allergic reaction sites

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Peripheral H1-blockade effect of fexofenadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Clinical pharmacology of new histamine H1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Effect of H1-receptor blockade on late cutaneous reactions to antigen: A double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Accumulation of leukotriene C4 and histamine in human allergic skin reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Vascular effects of leukotriene D4 in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Leukotriene- and Histamine-Induced Increases in Vascular Permeability and Interstitial Transport in the Skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

The effect of leukotriene C4 and D4 on cutaneous blood flow in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

The effect of the oral leukotriene antagonist, ICI 204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Leukotriene-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Montelukast: a review of its therapeutic potential in persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Characterization of the human cysteinyl leukotriene CysLT1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Leukotriene modifiers in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962354-X

7 January 2021

10.1016/S1081-1206(10)62354-X

Identifiers

DOI

1 reference

5 July 2017

1 reference